Atezolizumab ( DrugBank: Atezolizumab )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	2

85. 特発性間質性肺炎

---

臨床試験数 : 627 /  薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05515627 (ClinicalTrials.gov)	February 15, 2023	12/8/2022	Atezolizumab for Idiopathic Pulmonary Fibrosis	A Phase I Study to Evaluate the Safety and Preliminary Efficacy of Atezolizumab in Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: Atezolizumab	Cedars-Sinai Medical Center	Genentech, Inc.	Recruiting	50 Years	80 Years	All	24	Phase 1	United States
2	JPRN-jRCTs031190084	05/09/2019	27/08/2019	TORG1936 / AMBITIOUS study	A phase II study of Atezolizumab for advanced / recurrent Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias - TORG1936 / AMBITIOUS study	Advanced / recurrent Non-small cell lung cancer with idiopathic interstitial pneumonia	Atezolizumab 1200mg, every 3 weeks	KATO Terufumi	IKEDA Satoshi	Complete	>= 20age old	Not applicable	Both	38	Phase 2	Japan